Personalized, Randomized, Phase 2 Study of Pembrolizumab (MK-3475) for High Risk Oral Intra-Epithelial Neoplasias
Phase of Trial: Phase II
Latest Information Update: 21 Jun 2017
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Carcinoma; Glandular and epithelial neoplasms
- Focus Therapeutic Use
- 14 Jun 2017 Planned End Date changed from 1 Jul 2024 to 1 Jun 2024.
- 14 Jun 2017 Planned primary completion date changed from 1 Jul 2024 to 1 Jun 2024.
- 14 Jun 2017 Status changed from not yet recruiting to recruiting.